GlassScriptPhysician profile
Jeffrey Gutman
NPI 1083649248
$1,548.64
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $103 · 2020: $345 · 2021: $175 · 2022: $695 · 2023: $63.81 · 2024: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $231.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $230.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $443.46 | 2022 | |
| Acell, INC. | $411.97 | 2019-2020 | |
| Integra Lifesciences Corporation | $126.65 | 2021-2024 | Integra, Integra Dermal Regeneration Template, Surgimend |
| Innocoll Pharmaceuticals Limited | $87.68 | 2021-2022 | |
| Biotissue Holdings INC. | $82.61 | 2024 | |
| Heron Therapeutics, INC. | $63.35 | 2021-2022 | |
| Baxter Healthcare | $56.06 | 2022-2023 | Tisseel |
| Davol INC. | $42.51 | 2019-2021 | |
| Ethicon US, LLC | $39.34 | 2021-2022 | |
| Alfasigma USA, INC. | $35.08 | 2022 | |
| Springworks Therapeutics, INC. | $33.38 | 2024 | Ogsiveo |
| Reprise Biomedical, INC. | $29.59 | 2023 | Miro3d |
| Trevena, INC. | $23.84 | 2021 | |
| Smith+Nephew, INC. | $21.88 | 2024 | Grafix |
| Kowa Pharmaceuticals America, INC. | $18.38 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $17.84 | 2021 | |
| Covidien LP | $15.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Gutman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.